Pharmaceutical Executive February 1, 2024
A look at how legislation—and the wider quest for more transparency on drug costs and reimbursement—may impact manufacturer product launch and pricing strategies in the years ahead.
Jesse Mendelsohn, senior vice president of Model N, recently spoke with Pharmaceutical Executive on the complicated and changing complexion around drug pricing, access, and reimbursement in healthcare—including emerging hurdles biopharma companies are facing to bring new products to the market.
Whether it’s battling long-held reputational perceptions, navigating looming mandates from the Inflation Reduction Act (IRA), or adapting to new and alternative pharmacy payment models, it’s become an increasingly “delicate dance” for manufacturers to price competitively and maintain margins.
The following conversation was edited for...
Today's Sponsors
Today's Sponsor